FIMEA renews Nanoform’s GMP license and Nanoform starts clinical API manufacturing of a blockbuster medicine candidate
Press release Nanoform Finland Plc May 9, 2023 15.00 Finnish time / 14.00 Swedish time FIMEA renews Nanoform’s GMP license and Nanoform starts clinical API manufacturing of a blockbuster medicine candidate Helsinki, Finland – Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, are delighted to announce that FIMEA (Finnish Medicines Agency) has completed another successful general good manufacturing practices (GMP) inspection of Nanoform. During the inspection on March 28[th], 2023, FIMEA fully reviewed Nanoform for compliance with its processes and